BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Semafore Pharmaceuticals, Inc. 

8496 Georgetown Road

Indianapolis  Indiana  46268  U.S.A.
Phone: 317-876-3075 Fax: 317-872-1379


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Founded in 2000, Semafore is a small molecule drug discovery and development company that is targeting the PI3 kinase (PI3K) and PTEN cell signaling pathway to create a portfolio of innovative oncology products expected to have significant benefits over existing and developmental therapies. Increasing recognition of the central role of PI3K/PTEN in regulating cell life and death is making this pathway a prime target for drug discovery and development related to oncology, immunology and other diseases. Semafore is in pre-IND stages of drug development with a clinical candidate in its small molecule PI3K program, SF1126, expecting to enter clinical trials in late 2005 in prostate, breast, and brain cancer - cancers heavily dependent on PI3K. The company is also developing small molecule PTEN inhibitors, which have potential application in cancer and in diseases where safeguarding cell survival is crucial, including protection of the bone marrow during chemotherapy and to protect the heart from ischemia and reperfusion injury. early preclinical development in the PTEN program. Semafore has ambitious scientific and business development programs well underway. Semafore is developing a leadership position in PI3K/PTEN pathway expertise, discovery platforms, and drug products, and is assembling the core people required to discover and develop the next generation of cancer therapies.

  • Pathway: Genetic aberrations in signaling pathways are the best current indicators of success for therapy, and there are more genetic aberrations in the PI3K pathway than any other pathway.
  • Products: Semafore has a lead clinical candidate (SF1126 - PI3K Inhibitor) and has established a solid preclinical pipeline of small molecule PI3K and PTEN inhibitors with multi-billion dollar commercial potential.
  • Platforms: Semafore is applying its small molecule drug discovery engine to simultaneously exploit the Interceptors(tm) PI3K inhibitor and MarrowShield(tm) PTEN inhibitor platforms.
  • People: Combining biology, chemistry, drug development and entrepreneurial experience with support from world-leading scientific & clinical thought leaders Semafore is well positioned to execute its near-term strategy.

    Semafore's lead products are expected to have significant efficacy advantages compared to existing and developmental cancer therapies. For more information, see the company's Web site www.semaforepharma.com.

    Last Updated: 03-28-05

     Key Statistics


    Email: CompanyInfo@semaforepharma.com
    Ownership: Private

    Web Site: Semafore Pharmaceuticals, Inc.
    Employees:
    Symbol: 
     



  • Industry
    Biotechnology

    Segment
    Drug Discovery





     Company News
    Semafore Pharmaceuticals, Inc. to Present SF1126 Clinical Data at American Society of Clinical Oncology Annual Meeting 5/26/2011 9:19:18 AM
    Semafore Pharmaceuticals, Inc. Reports New Preclinical Data for Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at American Association for Cancer Research 4/5/2011 1:20:44 PM
    Semafore Pharmaceuticals, Inc. Announces Presentation Highlighting Activity of Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at 2011 American Association for Cancer Research Annual Meeting 3/9/2011 9:24:15 AM
    Semafore Pharmaceuticals, Inc. Receives FDA Orphan Drug Designation for SF1126 in the Treatment of Chronic Lymphocytic Leukemia 11/9/2010 11:24:59 AM
    Semafore Pharmaceuticals, Inc. Announces Issuance of U.S. Patent Covering Method of Use for PI3K Inhibitors 6/29/2010 10:25:51 AM
    Semafore Pharmaceuticals, Inc. Presents New Clinical Data on Novel Prodrug Dual PI3K-mTOR Inhibitor in B-Cell Malignancies and Solid Tumors 6/21/2010 8:32:17 AM
    Semafore Pharmaceuticals, Inc. Announces Issuance of Key U.S. Patent Covering Composition of Matter for Novel PI3K/mTOR Pathway Inhibitor 2/22/2010 10:02:05 AM
    Semafore Pharmaceuticals, Inc. Reports Encouraging Phase I Data at American Society of Hematology for Novel PI3K/mTOR Pathway Inhibitor 12/8/2009 9:36:29 AM
    Semafore Pharmaceuticals, Inc. Announces Phase I Data Presentation Highlighting Novel PI3K Pathway Inhibitor at 51st American Society of Hematology Annual Meeting 11/16/2009 9:25:08 AM
    Semafore Pharmaceuticals, Inc. Retains Management Consulting Firm; Names Principal to Key Management Position 9/21/2009 9:37:07 AM
    1234